PPARγANDGLUCOSEHOMEOSTASIS
Top Cited Papers
- 1 July 2002
- journal article
- review article
- Published by Annual Reviews in Annual Review of Nutrition
- Vol. 22 (1) , 167-197
- https://doi.org/10.1146/annurev.nutr.22.010402.102808
Abstract
▪ Abstract Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor involved in the control of metabolism. Research on PPARγ is oriented towards understanding its role in insulin sensitization, which was inspired by the discovery that antidiabetic agents, the thiazolidinediones, were agonists for PPARγ. PPARγ stimulation improves glucose tolerance and insulin sensitivity in type 2 diabetic patients and in animal models of insulin resistance through mechanisms that are incompletely understood. Upon activation, PPARγ heterodimerizes with retinoid X receptor, recruits specific cofactors, and binds to responsive DNA elements, thereby stimulating the transcription of target genes. Because PPARγ is highly enriched in adipose tissue and because of its major role in adipocyte differentiation, it is thought that the effects of PPARγ in adipose tissue are crucial to explain its role in insulin sensitization, but recent studies have highlighted the contribution of other tissues as well. Although relatively potent for their insulin-sensitizing action, currently marketed PPARγ activators have some important undesirable side effects. These concerns led to the discovery of new ligands with potent antidiabetic properties but devoid of certain of these side effects. Data from human genetic studies and from PPARγ heterozygous knockout mice indicate that a reduction in PPARγ activity could paradoxically improve insulin sensitivity. These findings suggest that modulation of PPARγ activity by partial agonists or compounds that affect cofactor recruitment might hold promise for the treatment of insulin resistance.Keywords
This publication has 224 references indexed in Scilit:
- Effects of Troglitazone on Cellular Differentiation, Insulin Signaling, and Glucose Metabolism in Cultured Human Skeletal Muscle CellsBiochemical and Biophysical Research Communications, 2001
- Fenofibrate and Rosiglitazone Lower Serum Triglycerides with Opposing Effects on Body WeightBiochemical and Biophysical Research Communications, 2000
- The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 DiabetesBiochemical and Biophysical Research Communications, 2000
- Regulation of Gene Expression by Activation of the Peroxisome Proliferator-Activated Receptor γ with Rosiglitazone (BRL 49653) in Human AdipocytesBiochemical and Biophysical Research Communications, 1999
- Pro12Ala Missense Mutation of the Peroxisome Proliferator Activated Receptor γ and Diabetes MellitusBiochemical and Biophysical Research Communications, 1999
- Pleuropulmonary Disease in a Man with Diabetes Who Was Treated with TroglitazoneNew England Journal of Medicine, 1998
- Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte DifferentiationNew England Journal of Medicine, 1998
- Expression of Peroxisome Proliferator-Activated Receptor γ (PPARγ) in Rat Aortic Smooth Muscle CellsBiochemical and Biophysical Research Communications, 1998
- Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor γ (hPPARγ) Gene in Diabetic Caucasians: Identification of a Pro12Ala PPARγ2 Missense MutationBiochemical and Biophysical Research Communications, 1997
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994